Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a single centre, randomized, double-blind, placebo-controlled, single ascending dose
study, in which the safety and pharmacokinetics of laninamivir octanoate administered by
inhalation via the TwinCaps® DPI will be assessed in adults with mild or moderate chronic
asthma.